Remove Access Remove Blog Remove Data
article thumbnail

What Could Rescheduling Mean for Medical Cannabis Patients?

Canna Care Docs

In this blog, we’ll break down what the big news means and what could happen next. Rescheduling would ease those research barriers, improving access to data and education around the plant and opening the door to fully explore the medical benefits cannabis could provide. What does rescheduling actually mean?

Patients 111
article thumbnail

Australia Cannabis Q&A

Canna Law Blog

Several proposals aim to: Expand medicinal cannabis access. Data Privacy 29. What data privacy obligations do cannabis businesses have? Given the sensitive nature of medicinal cannabis information, businesses must comply with the Privacy Act 1988, including: Secure storage of patient data. Increase export opportunities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cannabis Track and Trace Is A Disaster Waiting to Happen—and Not for the Reasons You Might Think

Canna Law Blog

The aspect of track-and-trace with the biggest potential for disaster isn’t the fact that it’s so complex, but rather the fact that loss of access to the system could be devastating for licensees. This leads me to a post I wrote several months ago on how data breaches are likely to ravage the cannabis industry.

Data 95
article thumbnail

Sequencing Cannabis Genetics for IP Protection: 4 Things to Consider

Medicinal Genomics

Editor’s Note: This following blog is an excerpt from an article that appeared in the March/April 2019 issue of Terpenes & Testing Magazine. Whole Genome Data. When it comes to sequencing your cultivar’s genetics for IP purposes, the more data the better. View the full article. . Publish to the Blockchain.

Data 94
article thumbnail

Psilocybin Patenting and the Threat to Patient Access

Cannabis Law Report

This blog post will explain how psilocybin patenting and other factors could make Oregon’s psilocybin program prohibitively expensive for low-income patients, and how big pharma is maneuvering to monopolize psychedelic therapy. The FDA will likely refer to this data as it considers formal approval for psilocybin therapy and products.

Access 52
article thumbnail

Study: marijuana Access Reduces Demand for Opioids Among Pain

The Joint Blog

PatientsAccording to a new study, access to cannabis reduces pain patients’ perceived demand for opioids. CONCLUSIONS: These data provide behavioral economic evidence that cannabis access may modestly reduce demand for opioids in persons who have pain. You can find more information on this study by clicking here.

Access 49
article thumbnail

Rest in Peace Mark Kleiman, Giant of Cannabis Policy

Canna Law Blog

All of us at Canna Law Blog were saddened to learn that the estimable Mark Kleiman passed away over the weekend. His views were creative and nuanced, data-driven and humanitarian. For just a few of his greatest (and most accessible) hits, check out the following: “ We’re Legalizing Weed Wrong ” (Top 10 list for Slate).

Policy 89